Steven Frucht
Steven Frucht has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Paul H. Gordon
Northern Navajo Medical Center, Shiprock, New Mexico, USA
1 shared publication
Latest Publications
- 1 September 2001
- Published by Wiley in Movement Disorders
- Vol. 16 (5) , 960-962
Neuroleptic malignant syndrome in advanced Parkinson's disease
Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease. We report a patient with advanced parkinsonism who developed neuroleptic malignant syndrome in the setting of inadequate levodopa intake. His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa. © 2001 Movement Disorder Society.
- 1 September 2001
- Published by Wiley in Movement Disorders
- Vol. 16 (5) , 960-962
Neuroleptic malignant syndrome in advanced Parkinson's disease
Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease. We report a patient with advanced parkinsonism who developed neuroleptic malignant syndrome in the setting of inadequate levodopa intake. His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa. © 2001 Movement Disorder Society.
- 1 May 2000
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 2 (3) , 231-241
Myoclonus
The diagnosis and treatment of myoclonus pose a particular challenge to the neurologist. Few well-controlled double-blind studies of antimyoclonic agents have been performed, and clinical rating of the effectiveness of treatment has been primarily descriptive. As a result, therapy is often empiric. This article reviews the author’s approach to treating patients with myoclonus. Three principles guide treatment. First, the cause and physiology of the myoclonic jerks must be ascertained before choosing the appropriate therapy. Second, multiple drugs often must be used in combination to achieve functional improvement. Third, given the paucity of adequately controlled trials, the treating physician must rely on well-documented case series of patients with myoclonic syndromes who obtained benefit from a drug.
- 1 May 2000
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 2 (3) , 231-241
Myoclonus
The diagnosis and treatment of myoclonus pose a particular challenge to the neurologist. Few well-controlled double-blind studies of antimyoclonic agents have been performed, and clinical rating of the effectiveness of treatment has been primarily descriptive. As a result, therapy is often empiric. This article reviews the author’s approach to treating patients with myoclonus. Three principles guide treatment. First, the cause and physiology of the myoclonic jerks must be ascertained before choosing the appropriate therapy. Second, multiple drugs often must be used in combination to achieve functional improvement. Third, given the paucity of adequately controlled trials, the treating physician must rely on well-documented case series of patients with myoclonic syndromes who obtained benefit from a drug.